코그니션 테라퓨틱스(CGTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.07 (+0.94%), 시가총액 $0.10B, 52주 최저~최고 $0.24 ~ $3.18.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is bas
코그니션 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
코그니션 테라퓨틱스의 현재 주가는 $1.07 (+0.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
코그니션 테라퓨틱스의 시가총액은 약 $0.10B입니다.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disord